Elafibranor

Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis. Elafibranor is a dual PPARα/δ agonist. Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro.

In June 2024, the US Food and Drug Administration (FDA) granted accelerated approval to elafibranor. The FDA considers it to be a first-in-class medication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378032425 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

19 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.